Drug news

NICE recommends Velcade (bortezomib) from Janssen Cilag VR-CAP combination to treat Mantle Cell Lymphoma- Janssen Cilag + Takeda Oncology

Read time: 1 mins

Last updated:27th Dec 2015

Published:27th Dec 2015

Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) has recommended Velcade (bortezomib) from Janssen Cilag + Takeda Oncology, with rituximab, doxorubicin and prednisone (VR-CAP) as a treatment for previously untreated mantle cell lymphoma. The decision was based on the Phase III LYM 3002 study where the combination was shown to extend progression free survival (PFS) by 10.3 months compared to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Patients in the VR-CAP combination had a median PFS of 24.7 months compared to 14.4 months for those treated with the R-CHOP combination.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approval for Kalydeco to treat infants with cystic fibrosis ages 1 month and older.- Vertex.

Vertex Pharmaceuticals announced that the European Commission has granted approval for the label expansion of Kayydeco (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

1 mins

Drug news

Novavax is prepared to deliver protein-based non-mRNA JN.1 COVID-19 vaccine in line with WHO recommendation this fall.

Novavax is Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall

1 min

Drug news

CHMP positive for Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.- Idorsia Ltd.

Idorsia Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.

1 min

See all news